The global fondaparinux market is estimated to grow at a CAGR of nearly 7.5% during the forecast period. Significant rise in the prevalence of arthritis is primarily driving the global fondaparinux market. As per the Centers for Disease Control and Prevention (CDC), by 2040, the number of adults aged 18 years and over in the US with doctor-diagnosed arthritis is estimated to rise 49% to 78.4 million (25.9% of the estimated total US adult population), compared to 54.4 million adults in 2013–2015. Additionally, as per the Versus Arthritis, in UK, musculoskeletal conditions including arthritis and back pain affected nearly 18.8 million people in 2017.

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/fondaparinux-market

Osteoarthritis is the most common form of arthritis that are affecting millions of people globally. Globally, over 200 million women suffer from osteoporosis. 1 in 3 postmenopausal women has osteoporosis, which increases with age. Therefore, increasing prevalence of geriatric population is also a major cause for the rising incidences of osteoarthritis. As per the United Nations (UN), by 2050, 1 in 6 people globally will be more than the age of 65, increased from 1 in 11 in 2019. In 2019, 703 million people were aged 65 years or over globally, which is expected to double to 1.5 billion in 2050.

A Full Report of Global Fondaparinux Market is Available at: https://www.omrglobal.com/industry-reports/fondaparinux-market

Osteoporosis commonly affects joints in hips, knees, spine, and hands, which results in the increasing number of hip and knee replacements. As per the Canadian Institute for Health Information (CIHI), in 2017-2018, 70,502 knee replacements and 58,492 hip replacements were performed in Canada. This shows a rise of 17.0% and 17.4%, respectively, over the last 5 years. According to the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR), there were a total of 242,629 cases registered to NJR during 2016/2017. It has shown a significant rise of over 20,000 joint replacement procedures than the previous year. This, in turn, is contributing to the adoption of fondaparinux to prevent deep vein thrombosis (blood clot) after the procedure.

Fondaparinux is used for the treatment of severe blood clots in the lungs or legs. It is often utilizing with another blood thinner drugs (warfarin). If blood clots are untreated, it can travel to the brain, heart, or lungs, causing serious breathing problems, stroke, or heart attack. Fondaparinux is further used for the prevention of blood clots after some procedures with an increased risk of blood clots, including knee and hip replacements, abdominal surgery, and hip fracture. Fondaparinux works similarly like heparin that blocks the activity of some clotting substances in the blood. However, fondaparinux has a longer half-life than heparin and does not interact with platelets. This, in turn, is contributing to the growth of the global fondaparinux market.

Global Fondaparinux Market- Segmentation

By Product Type

Branded
Generics

Global Fondaparinux Market– Segment by Region

North America

United States
Canada

Europe

Germany
UK
France
Spain
Italy
Rest of Europe

Asia-Pacific

China
Japan
India
Rest of Asia-Pacific

Rest of the World

Company Profiles

Apicore LLC
Aurobindo Pharma Ltd.
Cadila Healthcare Ltd. (CHL)
Dr Reddy’s Laboratories Ltd.
GlaxoSmithKline plc
Italfarmaco S.p.A.
Mylan N.V.
Sandoz International GmbH
ScinoPharm Taiwan, Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/fondaparinux-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404